| Abstract: | We describe a parkinsonian patient who developed a slight asymptomatic pleural effusion during prolonged therapy with low dose bromocriptine (BCR) in addition to levodopa, following prior treatment with CQA 206–291. A moderate increase of BCR dosage prompted a severe pleuropulmonary inflammatory reaction with polyclonal activation and elevated serum liver enzymes, which normalized following withdrawal of the drug. The clinical syndrome and close relation to BCR treatment are in keeping with a diagnosis of BCR-related pleuropulmonary fibrosis (PPF). Features of this case are compared with previous reports on dopamine (DA) agonist-related PPF. This case supports earlier suggestions of polyclonal activation in DA agonist-related PPF and suggests hepatic involvement and dose dependency. |
